Marion Munk

Company: Isarna THerapeutics

Job title: Chief Medical Officer

Seminars:

Targeting TGF beta 2 mRNA Using Antisense Technology as a New Therapeutic Option in Retinal Diseases 2:00 pm

Targeting TGF beta 2 mRNA using antisense technology as a new therapeutic option in retinal diseases Our lead compound ISTH0036 is a first in class selective second-generation antisense oligonucleotide (ASO) blocking TGF-β2 The phase 1 dose escalation study confirmed the excellent safety profile Currently phase 2 trials are assessing efficacy in wet AMD and DMERead more

day: Day Two